Cargando…

Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer

PURPOSE: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical res...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagata, Ichiro, Ogino, Takashi, Arimura, Takeshi, Yoshiura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553652/
https://www.ncbi.nlm.nih.gov/pubmed/33117018
http://dx.doi.org/10.2147/LCTT.S270283
_version_ 1783593648766582784
author Nagata, Ichiro
Ogino, Takashi
Arimura, Takeshi
Yoshiura, Takashi
author_facet Nagata, Ichiro
Ogino, Takashi
Arimura, Takeshi
Yoshiura, Takashi
author_sort Nagata, Ichiro
collection PubMed
description PURPOSE: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical resection in these patients, this study aimed to examine the retrospective treatment outcomes of patients with GGO-type lung cancer who underwent PBT. PATIENTS AND METHODS: Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 2015 were included. Patients were treated with a total dose of 66 GyE delivered in 10 fractions. Survival curves were calculated using the Kaplan–Meier method, and treatment-related adverse events (AEs) were assessed. RESULTS: A total of 48 patients (median age: 70.9 ± 9.2 years; men: 54.2%) were analyzed, among whom 53 tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% confidence interval [CI], 79.3–96.8%), the 3-year disease-free survival rate was 85.4% (95% CI: 71.8–92.8%), and the 3-year local control rate among 53 tumors was 92.5% (95% CI: 81.1–97.1%). During the 3-year follow-up period, 4 patients died, and 3 survived despite recurrence or metastasis. Common AEs were radiation pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the patients developed grade ≥3 treatment-related AEs. CONCLUSION: The results of this study suggest that PBT may be a promising alternative for patients with GGO-type lung cancer when surgical resection is not feasible, with excellent survival outcomes and tolerable treatment-related AEs.
format Online
Article
Text
id pubmed-7553652
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75536522020-10-27 Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer Nagata, Ichiro Ogino, Takashi Arimura, Takeshi Yoshiura, Takashi Lung Cancer (Auckl) Original Research PURPOSE: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical resection in these patients, this study aimed to examine the retrospective treatment outcomes of patients with GGO-type lung cancer who underwent PBT. PATIENTS AND METHODS: Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 2015 were included. Patients were treated with a total dose of 66 GyE delivered in 10 fractions. Survival curves were calculated using the Kaplan–Meier method, and treatment-related adverse events (AEs) were assessed. RESULTS: A total of 48 patients (median age: 70.9 ± 9.2 years; men: 54.2%) were analyzed, among whom 53 tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% confidence interval [CI], 79.3–96.8%), the 3-year disease-free survival rate was 85.4% (95% CI: 71.8–92.8%), and the 3-year local control rate among 53 tumors was 92.5% (95% CI: 81.1–97.1%). During the 3-year follow-up period, 4 patients died, and 3 survived despite recurrence or metastasis. Common AEs were radiation pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the patients developed grade ≥3 treatment-related AEs. CONCLUSION: The results of this study suggest that PBT may be a promising alternative for patients with GGO-type lung cancer when surgical resection is not feasible, with excellent survival outcomes and tolerable treatment-related AEs. Dove 2020-10-09 /pmc/articles/PMC7553652/ /pubmed/33117018 http://dx.doi.org/10.2147/LCTT.S270283 Text en © 2020 Nagata et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Nagata, Ichiro
Ogino, Takashi
Arimura, Takeshi
Yoshiura, Takashi
Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_full Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_fullStr Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_full_unstemmed Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_short Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_sort clinical outcomes of proton beam therapy for ground-glass opacity-type lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553652/
https://www.ncbi.nlm.nih.gov/pubmed/33117018
http://dx.doi.org/10.2147/LCTT.S270283
work_keys_str_mv AT nagataichiro clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer
AT oginotakashi clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer
AT arimuratakeshi clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer
AT yoshiuratakashi clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer